Radiolabeling yield dependency of post-dry distillation decay of astatine-211

IF 3.6 4区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Ellinor Hansson , Chiara Timperanza , Holger Jensen , Björn Eriksson , Sture Lindegren , Emma Aneheim
{"title":"Radiolabeling yield dependency of post-dry distillation decay of astatine-211","authors":"Ellinor Hansson ,&nbsp;Chiara Timperanza ,&nbsp;Holger Jensen ,&nbsp;Björn Eriksson ,&nbsp;Sture Lindegren ,&nbsp;Emma Aneheim","doi":"10.1016/j.nucmedbio.2025.108999","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim/introduction</h3><div>Astatine-211 (<sup>211</sup>At) is one of the most promising nuclides for targeted alpha therapy. However, while several clinical trials are ongoing worldwide, some aspects of the element remain unexplored. This work aims to investigate changes in radiochemical yield over time, expressed as the number of <sup>211</sup>At decays, post-dry distillation using two common astatination reactions.</div></div><div><h3>Materials and methods</h3><div><sup>211</sup>At was purified from activated bismuth targets via dry distillation and eluted in chloroform. The solvated activity was then either evaporated to dryness or left in the chloroform eluate. Before chemical reactions, both forms of the starting material were allowed to age at room temperature for up to 28 h, correlating to 3 ∙ 10<sup>12 211</sup>At decays. All chemical reactions were subsequently started from a dry residue. Radiolabeling was carried out either via electrophilic destannylation of tri(methyl)phenylstannane, or via the nucleophilic substitution of bis(4-<em>tert</em>-butylphenyl)iodonium <em>p</em>-toluenesulfonate. Radiochemical yield was determined using a dual flow radiodetection HPLC method allowing direct yield quantification.</div></div><div><h3>Results</h3><div>In both cases, where <sup>211</sup>At was stored either as a dry residue or in chloroform, radiochemical yields decreased with increasing amounts of radioactive decay. This was true both for nucleophilic and electrophilic astatinations. In the case of <sup>211</sup>At stored in chloroform, the dose-yield relationship indicates a more rapid decrease for electrophilic astatination. However, decreases in radiochemical yield could be mitigated by increasing the precursor concentration, keeping yields constant above 80 % even when using <sup>211</sup>At after 28 h, corresponding up to 3 ∙ 10<sup>12 211</sup>At decays. There is also an indication that higher amounts of oxidizing/reducing agents and redissolution of dry <sup>211</sup>At in fresh chloroform may mitigate the loss in yield to some extent.</div></div><div><h3>Conclusion</h3><div>Radiochemical yields in labeling with <sup>211</sup>At decrease over time post dry distillation independent if the <sup>211</sup>At was kept dry or in chloroform. If high specific activity is a requirement for the final radiolabeled product, the most reliable way to maintain high yields is to perform the radiolabeling close in time after the dry distillation.</div></div>","PeriodicalId":19363,"journal":{"name":"Nuclear medicine and biology","volume":"144 ","pages":"Article 108999"},"PeriodicalIF":3.6000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuclear medicine and biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969805125000083","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Aim/introduction

Astatine-211 (211At) is one of the most promising nuclides for targeted alpha therapy. However, while several clinical trials are ongoing worldwide, some aspects of the element remain unexplored. This work aims to investigate changes in radiochemical yield over time, expressed as the number of 211At decays, post-dry distillation using two common astatination reactions.

Materials and methods

211At was purified from activated bismuth targets via dry distillation and eluted in chloroform. The solvated activity was then either evaporated to dryness or left in the chloroform eluate. Before chemical reactions, both forms of the starting material were allowed to age at room temperature for up to 28 h, correlating to 3 ∙ 1012 211At decays. All chemical reactions were subsequently started from a dry residue. Radiolabeling was carried out either via electrophilic destannylation of tri(methyl)phenylstannane, or via the nucleophilic substitution of bis(4-tert-butylphenyl)iodonium p-toluenesulfonate. Radiochemical yield was determined using a dual flow radiodetection HPLC method allowing direct yield quantification.

Results

In both cases, where 211At was stored either as a dry residue or in chloroform, radiochemical yields decreased with increasing amounts of radioactive decay. This was true both for nucleophilic and electrophilic astatinations. In the case of 211At stored in chloroform, the dose-yield relationship indicates a more rapid decrease for electrophilic astatination. However, decreases in radiochemical yield could be mitigated by increasing the precursor concentration, keeping yields constant above 80 % even when using 211At after 28 h, corresponding up to 3 ∙ 1012 211At decays. There is also an indication that higher amounts of oxidizing/reducing agents and redissolution of dry 211At in fresh chloroform may mitigate the loss in yield to some extent.

Conclusion

Radiochemical yields in labeling with 211At decrease over time post dry distillation independent if the 211At was kept dry or in chloroform. If high specific activity is a requirement for the final radiolabeled product, the most reliable way to maintain high yields is to perform the radiolabeling close in time after the dry distillation.

Abstract Image

求助全文
约1分钟内获得全文 求助全文
来源期刊
Nuclear medicine and biology
Nuclear medicine and biology 医学-核医学
CiteScore
6.00
自引率
9.70%
发文量
479
审稿时长
51 days
期刊介绍: Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信